Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hungarian Court Decision Threatens Unified Patent Court Viability

Executive Summary

Hungary has decided that Europe’s forthcoming Unified Patent Court Agreement is not compatible with its constitution. It will now be more important than ever to keep a close watch for possible new constitutional complaints in other countries.

You may also be interested in...



‘No-Deal’ Brexit: UK Would Keep Rules on Patents, SPCs & Parallel Trade

The latest “technical notices” from the government say that there will be no material change to the rules on intellectual property protections and compulsory licensing if the UK leaves the EU without a deal, and that the government also intends to continue allowing parallel imports of medicines from Europe to the UK.

One Less Worry For Europe's Unified Patent Court After UK Ratifies Key Agreement

Europe’s UPC still cannot start until and unless a legal challenge in Germany is settled in favor of the court, but the UK’s ratification this week means that discussions about the UK’s post-Brexit participation in the new systemcan now start properly.

MSD Removes ‘Key Barrier’ To English Funding For Keytruda In Triple-Negative Breast Cancer

MSD has agreed to restrict the use of its Keytruda combination therapy in a manner that means that Roche’s Tecentriq combination is no longer a direct comparator.

Topics

UsernamePublicRestriction

Register

PS123456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel